NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic “The first ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...

Investors might want to bet on atai Life Sciences N.V. (ATAI), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful ...

Shares of atai Life Sciences N.V. (ATAI) have been struggling lately and have lost 6.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on ...

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Safety and efficacy results from this study support ...